Skip to main content
. 2017 Jun 1;8(9):1507–1516. doi: 10.7150/jca.19175

Figure 4.

Figure 4

HCC recurrence after initial RFA therapy. (A) The 1-, 3-, 5- and 7-year cumulative local tumor progression rates were 2.8%, 9.1%, 9.1% and 9.1%, respectively. (B) The 1-, 3-, 5- and 7-year cumulative intrahepatic distant recurrence rates were 13.8%, 39.5%, 51.3% and 58.4%, respectively. (C) The 1-, 3-, 5- and 7-year cumulative recurrence free survival rates were 85.1%, 53.6%, 41.5% and 34.5%, respectively.